Phase 2
N=637
Promoting Informed Choice for Breast Cancer Screening
Breast Cancer
Bottom Line
View on ClinicalTrials.gov: NCT05376241 ↗Enrolled (actual)
637
Serious AEs
0.0%
Results posted
Oct 2025
Primary outcome: Primary: Reactance — 2.28; 2.45; 2.55 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Decision aid (Behavioral)
- Age
- Adult · 39+ yrs
- Sex
- Female
- Sponsor
- University of Colorado, Denver
- Primary completion
- May 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Reactance |
2.28; 2.45; 2.55 | — |
| PRIMARY Disbelief |
2.06; 2.32; 2.41 | — |
| PRIMARY Source Derogation |
2.56 | — |
| PRIMARY Self Exemption |
2.20; 2.21; 2.32 | — |
| PRIMARY Screening Intentions |
286; 100; 88; 21 | — |
| SECONDARY Medical Mistrust Scale (Eaton et al., 2015) |
3.11; 3.02 | — |
Summary
Identify the prevalence and predictors of reactance, self-exemption, disbelief, source derogation in reaction to evidence about mammography benefits and harms, and consequences for decision-making and trust.
Eligibility Criteria
Inclusion Criteria
- Female
- Between 39-49 years of age
- No history of breast cancer
- No known BRCA 1/2 mutation
Exclusion Criteria
- Non-English or Spanish Speaking
- Persons unable to provide informed consent (e.g. sever dementia or cognitive disability or illiterate
- History of breast cancer
- Known BRCA 1/2 mutation
Data sourced from ClinicalTrials.gov (NCT05376241). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.